Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000116.xml
Semin Vasc Med 2003; 03(2): 185-192
DOI: 10.1055/s-2003-40676
DOI: 10.1055/s-2003-40676
Tissue Factor in Acute Coronary Syndromes
Ilka Ott- Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Munich, Germany
Further Information
Publication History
Publication Date:
18 July 2003 (online)
ABSTRACT
Thrombosis at the site of atherosclerotic plaque disruption is the principal cause of acute coronary syndromes. The severity of the clinical consequences is determined by the extent and the progression of the thrombus that are caused by local and systemic factors. In atherosclerotic lesions mediators induce tissue factor (TF) in macrophages, smooth muscle cells, and endothelial cells. Procoagulant microparticles in the lipid core further enhance the thrombogenicity of the plaque. In addition, in acute coronary syndromes circulating monocytes and microparticles express TF and, thereby, contribute to systemic procoagulant activity. As a regulatory mechanism surface-bound, endogenous tissue factor pathway inhibitor-1 (TFPI) inhibits TF activity by translocation of the quaternary complex TF-FVIIa-FXa-TFPI into glycosphingolipid-rich microdomains more efficiently than exogenously added TFPI. This inhibition occurs not only in endothelial cells but also on circulating monocytes and presumably microparticles. Because therapeutic thrombolysis in acute myocardial infarction degrades TFPI, a prothrombotic state due to unopposed TF activity may occur. Several studies have demonstrated a contribution of local and bloodborne TF to thrombus formation; a direct relationship with the clinical outcome, however, awaits further studies. This article discusses the current understanding of the role of TF and its regulation by TFPI in acute coronary syndromes.
KEYWORDS
Tissue factor - acute coronary syndrome - coagulation - thrombolysis
REFERENCES
- 1 Zhou J, Chew M, Ravn H B. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Scand J Clin Lab Invest Suppl . 1999; 230 3-11
- 2 Tremoli E, Camera M, Toschi V. Tissue factor in atherosclerosis. Atherosclerosis . 1999; 144 273-283
- 3 Moss A J, Goldstein R E, Marder V J. Thrombogenic factors and recurrent coronary events. Circulation . 1999; 99 2517-2522
- 4 Ruf W. The interaction of activated factor VII with tissue factor: insight into the mechanism of cofactor-mediated activation of activated factor VII. Blood Coagul Fibrinolysis . 1998; 9 S73-S78
- 5 Wilcox J N, Smith K M, Schwartz S M. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA . 1989; 86 2839-2843
- 6 McVey J H. Tissue factor pathway. Baillieres Best Pract Res Clin Haematol . 1999; 12 361-372
- 7 Hatakeyama K, Asada Y, Marutsuka K. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis . 1997; 133 213-219
- 8 Thiruvikraman S V, Guha A, Roboz J. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest . 1996; 75 451-461
- 9 Marmur J D, Thiruvikraman S V, Fyfe B S. Identification of active tissue factor in human coronary atheroma. Circulation . 1996; 94 1226-1232
- 10 Mallat Z, Hugel B, Ohan J. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation . 1999; 99 348-353
- 11 Schecter A D, Spirn B, Rossikhina M. Release of active tissue factor by human arterial smooth muscle cells. Circ Res . 2000; 87 126-132
- 12 Mallat Z, Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol . 2000; 130 947-962
- 13 Zhang J, Reedy M C, Hannun Y A. Inhibition of caspases inhibits the release of apoptotic bodies: bcl-2 inhibits the initiation of formation of apoptotic bodies in chemotherapeutic agent-induced apoptosis. J Cell Biol . 1999; 145 99-108
- 14 Leatham E W, Bath P M, Tooze J A. Increased monocyte tissue factor expression in coronary disease. Br Heart J . 1995; 73 10-13
- 15 Ott I, Andrassy M, Zieglgansberger D. Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. Blood . 2001; 97 3721-3726
- 16 Kappelmayer J, Berecki D, Misz M. Monocytes express tissue factor in young patients with cerebral ischemia. Cerebrovasc Dis . 1998; 8 235-239
- 17 Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost . 2001; 27 605-617
- 18 Moons A H, Levi M, Peters R J. Tissue factor and coronary artery disease. Cardiovasc Res . 2002; 53 313-325
- 19 Corseaux D, Le Tourneau T, Six I. Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: inhibition with dietary L-arginine. Circulation . 1998; 98 1776-1782
- 20 Siddiqui F A, Desai H, Amirkhosravi A. The presence and release of tissue factor from human platelets. Platelets . 2002; 13 247-253
- 21 Giesen P L, Rauch U, Bohrmann B. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA . 1999; 96 2311-2315
- 22 Zillmann A, Luther T, Muller I. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun . 2001; 281 603-609
- 23 Lawson C, Ainsworth M, Yacoub M. Ligation of ICAM-1 on endothelial cells leads to expression of VCAM-1 via a nuclear factor-kappaB-independent mechanism. J Immunol . 1999; 162 2990-2996
- 24 Broze Jr J G. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med . 1995; 46 103-112
- 25 Broze Jr J G. Tissue factor pathway inhibitor. Thromb Haemost . 1995; 74 90-93
- 26 Ohkura N, Enjyoji K, Kamikubo Y. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood . 1997; 90 1883-1892
- 27 Li A, Wun T C. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost . 1998; 80 423-427
- 28 Salemink I, Franssen J, Willems G M. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost . 1998; 80 273-280
- 29 Higuchi D A, Wun T C, Likert K M. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood . 1992; 79 1712-1719
- 30 Belaaouaj A, Li A, Wun T. Matrix metalloproteinases cleave tissue factor pathway inhibitor: effects on coagulation. J Biol Chem . 2000; 275 27123-27128
- 31 Kato H. Tissue factor pathway inhibitor; its structure, function and clinical significance. Pol J Pharmacol . 1996; 48 67-72
- 32 Lupu C, Lupu F, Dennehy U. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol . 1995; 15 2055-2062
- 33 Hansen J B, Svensson B, Olsen R. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost . 2000; 83 937-943
- 34 Lupu C, Poulsen E, Roquefeuil S. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol . 1999; 19 2251-2262
- 35 Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol . 2002; 22 539-548
- 36 Sevinsky J R, Rao L V, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol . 1996; 133 293-304
- 37 Lupu C, Goodwin C A, Westmuckett A D. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol . 1997; 17 2964-2974
- 38 Ott I, Vukovitsch R, Ruf W. Glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor-1 gene transfer inhibits tissue factor activity in ECV304 cells. Ann Hematol . 2002; 81 (suppl 1) A62
- 39 Kojima T, Katsumi A, Yamazaki T. Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J Biol Chem . 1996; 271 5914-5920
- 40 Mast A E, Higuchi D A, Huang Z F. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J . 1997; 327 577-583
- 41 Ott I, Miyagi Y, Miyazaki K. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol . 2000; 20 874-882
- 42 Lupu C, Poulsen E, Roquefeuil S. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol . 1999; 19 2251-2262
- 43 Williamson T G, Mok S S, Henry A. Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP-induced neurite outgrowth. J Biol Chem . 1996; 271 31215-31221
- 44 Warshawsky I, Broze Jr J G, Schwartz A L. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA . 1994; 91 6664-6668
- 45 Warshawsky I, Herz J, Broze Jr J G. The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem . 1996; 271 25873-25879
- 46 Ho G, Broze Jr J G, Schwartz A L. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes. J Biol Chem . 1997; 272 16838-16844
- 47 Hamik A, Setiadi H, Bu G. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem . 1999; 274 4962-4969
- 48 Iakhiaev A, Pendurthi U R, Voigt J. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem . 1999; 274 36995-37003
- 49 Caplice N M, Mueske C S, Kleppe L S. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation . 1998; 98 1051-1057
- 50 Crawley J, Lupu F, Westmuckett A D. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol . 2000; 20 1362-1373
- 51 Kaikita K, Takeya M, Ogawa H. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol . 1999; 188 180-188
- 52 Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb Res . 1995; 80 339-348
- 53 Falciani M, Gori A M, Fedi S. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost . 1998; 79 495-499
- 54 Lindahl A K, Odegaard O R, Sandset P M. Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. Cancer . 1992; 70 2067-2072
- 55 Morange P E, Renucci J F, Charles M A. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost . 2001; 85 999-1003
- 56 Saigo M, Abe S, Ogawa M. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost . 2001; 86 1197-1203
- 57 Gando S, Kameue T, Morimoto Y. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med . 2002; 30 1729-1734
- 58 Broze Jr J G. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis . 1995; 6 S7-S13
- 59 Novotny W F, Girard T J, Miletich J P. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood . 1988; 72 2020-2025
- 60 Sandset P M, Warn-Cramer B J, Rao L V. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA . 1991; 88 708-712
- 61 Ragni M, Golino P, Cirillo P. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation . 2000; 102 113-117
- 62 Abraham E, Reinhart K, Svoboda P. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med . 2001; 29 2081-2089
- 63 Ardissino D, Merlini P A, Bauer K A. Thrombogenic potential of human coronary atherosclerotic plaques. Blood . 2001; 98 2726-2729
- 64 Tremoli E, Camera M, Toschi V. Tissue factor in atherosclerosis. Atherosclerosis . 1999; 144 273-283
- 65 Ott I, de Waha R, Koch W. Tissue factor promotor polymorphism is associated with increased risk of myocardial infarction. Eur Heart J . 2002; 23 227
- 66 Arnaud E, Barbalat V, Nicaud V. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. Arterioscler Thromb Vasc Biol . 2000; 20 892-898
- 67 Girelli D, Russo C, Ferraresi P. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med . 2000; 343 774-780
- 68 Agraou B, Corseaux D, McFadden E P. Effects of coronary angioplasty on monocyte tissue factor response in patients with stable or unstable angina. Thromb Res . 1997; 88 237-243
- 69 Jude B, Agraou B, McFadden E P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation . 1994; 90 1662-1668
- 70 Ott I, Neumann F J, Kenngott S. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. Am J Cardiol . 1998; 82 938-942
- 71 Neumann F J, Ott I, Marx N. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol . 1997; 17 3399-3405
- 72 Mackman N. Regulation of the tissue factor gene. FASEB J . 1995; 9 883-889
- 73 Serneri G, Abbate R, Gori A. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation . 1992; 86 790-797
- 74 Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol . 2000; 20 2322-2328
- 75 Suefuji H, Ogawa H, Yasue H. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J . 1997; 134 253-259
- 76 Misumi K, Ogawa H, Yasue H. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol . 1998; 81 22-26
- 77 Soejima H, Ogawa H, Yasue H. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation . 1999; 99 2908-2913
- 78 Marco J, Ariens R A, Fajadet J. Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris. Am J Cardiol . 2000; 85 527-531
- 79 Kim H K, Song K S, Park Y S. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology . 2000; 93 31-36
- 80 Nishiyama K, Ogawa H, Yasue H. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J . 1998; 62 710-712
- 81 Roldan V, Marin F, Fernandez P. Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction. Int J Cardiol . 2001; 78 115-119
- 82 Kamikura Y, Wada H, Yamada A. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol . 1997; 55 183-187
- 83 Sandset P M, Sirnes P A, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol . 1989; 72 391-396
- 84 Mallat Z, Benamer H, Hugel B. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation . 2000; 101 841-843
- 85 Gawaz M, Neumann F J, Ott I. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation . 1996; 93 229-237
- 86 Dignat-George F, Blann A, Sampol J. Circulating endothelial cells in acute coronary syndromes. Blood . 2000; 95 728
- 87 Mesri M, Altieri D C. Endothelial cell activation by leukocyte microparticles. J Immunol . 1998; 161 4382-4387
- 88 Sabatier F, Roux V, Anfosso F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood . 2002; 99 3962-3970
- 89 Boulanger C M, Scoazec A, Ebrahimian T. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation . 2001; 104 2649-2652
- 90 Ott I, Malcouvier V, Schomig A. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation . 2002; 105 279-281
- 91 Stalboerger P G, Panetta C J, Simari R D. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor. Thromb Haemost . 2001; 86 923-928
- 92 Steppich B, Malcouvier V, Geith S. Proteolysis of tissue factor pathway inhibitor-1 after thrombolysis in acute myocardial infarction. Eur Heart J . 2002; 23 262
- 93 Petersen L C. Active site-inhibited seven: mechanism of action including signal transduction. Semin Hematol . 2001; 38 39-42
- 94 Houston D S. Tissue factor-a therapeutic target for thrombotic disorders. Expert Opin Ther Targets . 2002; 6 159-174